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OBJECTIVES AND WORK PLAN
Current cancer treatments include surgical interven-
tion, radiation and chemotherapeutic drugs; how-
ever these therapies are non-specific resulting in the 
destruction of both tumor and healthy cells. In this 
sense, the development of a targeted drug delivery 
system is highly desirable. This approach consists 
essentially in designing smart new anticancer ther-
apeutics meant to specifically target some unique 
aspects of tumor biology. Such drug delivery systems 
should enable improved biodistribution, tissue uptake 
and pharmacokinetics of therapeutic agents. Nano-
carrier-based drug delivery offers several advantages 
such as an increase of drug stability and bioavailabil-
ity, by preventing its early degradation, the ability to 
deliver therapeutic agents, and thus reduce non-spe-
cific toxicity. The aim of this PhD project is to develop 
a targeted therapeutic nanocarrier for the treatment 
of cancer. The isolation of novel targeting moieties – 
aptamers - for cancer cells shall be achieved through 
the SELEX technique. This methodology consists in 
the use of a random library of single-stranded DNA 
or RNA, flanked by two primer-binding regions, and 
uses an iterative process that specifically amplifies 
sequences that have high binding affinity to a given tar-
get. In several selection rounds, binders are amplified 
and nonspecific binders are removed in a partition-
ing step. Furthermore, a rationally designed gene 
silencing siRNA will be used as a therapeutic agent, 
directed to targets in relevant pathways involved in the 
development and proliferation of breast cancer cells. 
The siRNA will follow conjugation to previously iso-
lated aptamers. This may be achieved either directly 
or to an encapsulated form of the therapeutic agent 
in a nanocarrier. In the case of nanocarrier encapsu-
lation, these will enhance the stability, bioavailability 
and selectivity of these constructs. But more impor-
tantly, the ability to design materials with controlled 
crosslinking density determining material fate would 
enable to program the delivery rate of the therapeu-
tic agents and prolonging its duration in vivo. The 
delivery and internalization of the conjugated aptam-
er-siRNA or nanocarrier will be studied and ultimately, 
the optimization of the delivery system is predicted. 
These studies will primarily undergo in vitro validation 
using various cancer cell models. Eventually, in vivo 
studies shall also be conducted.
RESULTS
Ongoing cycles of SELEX. Culture optimization of 
different cell lines and establishment of procedures 
for siRNA transfection and protein expression.
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